Transarterial therapies in HCC: Does embolization increase survival?

Journal of Hepatology

Volumn 51, Issue 6, 2009, Pages 981-983

  Forner, Alejandro ^a   Trinchet, Jean Claude ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b HÔPITAL JEAN VERDIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ARTERY BLOOD FLOW; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; CHRONIC LIVER DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; EDITORIAL; HUMAN; LIVER CELL CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZATION; TREATMENT RESPONSE;

CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; SURVIVAL RATE;

EID: 71849111321     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.09.009     Document Type: Editorial

References (12)

1. Llovet J.M., Di Bisceglie A.M., Bruix J., Kramer B.S., Lencioni R., Zhu A.X., et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100 (2008) 698-711
2. Bruix J., and Sherman M. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
3. Llovet J.M., Real M.I., Montana X., Planas R., Coll S., Aponte J., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002) 1734-1739
4. Lo C.M., Ngan H., Tso W.K., Liu C.L., Lam C.M., Poon R.T., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (2002) 1164-1171
5. Llovet J.M., and Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37 (2003) 429-442
6. Beaugrand M., and Trinchet J.C. Interventional radiology as a fine art. J Hepatol 46 (2007) 362-364
7. Okusaka T., Kasugai H., Shioyama Y., Tanaka K., Kudo M., Saisho H., et al. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol 51 (2009) 1030-1036
8. Moher D., Schulz K.F., and Altman D.G. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 134 (2001) 657-662
9. Varela M., Real M.I., Burrel M., Forner A., Sala M., Brunet M., et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46 (2007) 474-481
10. Malagari K., Chatzimichael K., Alexopoulou E., Kelekis A., Hall B., Dourakis S., et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 31 (2008) 269-280
11. Poon R.T., Tso W.K., Pang R.W., Ng K.K., Woo R., Tai K.S., et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 5 (2007) 1100-1108
12. Lencioni R., Crocetti L., Petruzzi P., Vignali C., Bozzi E., Della Pina C., et al. Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study. J Hepatol 49 (2008) 217-222